Volume | 274,327 |
|
|||||
News | - | ||||||
Day High | 0.749899 | Low High |
|||||
Day Low | 0.7151 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cidara Therapeutics Inc | CDTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.72 | 0.7151 | 0.749899 | 0.722 | 0.7222 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
635 | 274,327 | $ 0.7269089 | $ 199,411 | - | 0.593 - 1.48 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:58 | formt | 100 | $ 0.77 | USD |
Cidara Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
65.11M | 90.43M | - | 64.29M | -29.8M | -0.33 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cidara Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CDTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.93 | 0.9599 | 0.69 | 0.7755061 | 610,962 | -0.16 | -17.20% |
1 Month | 0.78 | 1.22 | 0.69 | 0.9461174 | 1,122,800 | -0.01 | -1.28% |
3 Months | 0.6715 | 1.22 | 0.625 | 0.8190311 | 723,255 | 0.0985 | 14.67% |
6 Months | 0.905 | 1.22 | 0.593 | 0.8020564 | 640,466 | -0.135 | -14.92% |
1 Year | 1.15 | 1.48 | 0.593 | 0.9681927 | 703,485 | -0.38 | -33.04% |
3 Years | 2.10 | 2.39 | 0.40 | 1.24 | 816,193 | -1.33 | -63.33% |
5 Years | 2.43 | 4.45 | 0.40 | 1.58 | 643,729 | -1.66 | -68.31% |
Cidara Therapeutics Description
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. |